A New 'Average' Human Genome Maps Disease Risk for Everyone
A team led by the University of Exeter has published what it describes as the first characterization of an ‘average’ human genome, a reference portrait of the genetic variation carried by a typical person. The work, reported in the journal Genome Medicine, draws on two major population biobanks and covers nearly one million individuals, including whole-genome sequencing data. The goal is not to describe a real person but to establish a baseline against which any individual’s genetic profile can be compared.
The central claim is striking in its simplicity: regardless of an individual’s current health, their genetic features alone can be used to judge the risk that they will develop a given disease. That shifts the emphasis from what a patient is experiencing now to what their DNA suggests may lie ahead, a subtle but important change in how risk is framed.
The study analyzed data from two large population biobanks, repositories that combine genetic samples with health records and lifestyle information across hundreds of thousands of volunteers. By pooling nearly a million genomes, the researchers could identify patterns that smaller studies miss, separating genuine biological signal from the noise of individual variation. The resulting average genome is a statistical construct, but it gives clinicians and researchers a common yardstick.
For global readers, the implications reach beyond the laboratory. Genetic risk scoring is already moving into clinical use in several countries, and a reliable average genome could make those scores more comparable across populations and studies. It could also help flag people who would benefit from earlier screening, particularly for conditions where family history is incomplete or unknown.
The work also raises familiar questions. Genetic risk is probabilistic, not destiny, and experts caution that an elevated score does not mean a person will become ill. Environmental factors, lifestyle and access to care remain powerful. An average genome built largely from biobank volunteers may also under-represent populations that have historically been left out of genetic research, a limitation the field has been grappling with for years.
Still, the paper adds a useful piece of infrastructure to a fast-moving area. As more genomes are sequenced and more risk models are validated, the idea of a shared baseline could become as ordinary as a growth chart in a pediatrician’s office, a tool for placing one person’s data in context rather than a verdict about their future.